PDS Planning Inc Decreases Stock Position in Johnson & Johnson $JNJ

PDS Planning Inc lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 1.3% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 18,343 shares of the company’s stock after selling 243 shares during the period. PDS Planning Inc’s holdings in Johnson & Johnson were worth $2,802,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of JNJ. GFG Capital LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth $35,000. Highline Wealth Partners LLC raised its stake in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the first quarter valued at about $48,000. Finally, von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson in the first quarter worth about $49,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.2%

Shares of NYSE JNJ opened at $190.66 on Monday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $192.10. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a fifty day simple moving average of $178.48 and a 200-day simple moving average of $163.78. The stock has a market capitalization of $459.16 billion, a PE ratio of 20.39, a PEG ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $24.02 billion during the quarter. On average, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s payout ratio is presently 55.61%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

JNJ has been the subject of several research analyst reports. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 price objective on shares of Johnson & Johnson in a report on Friday. Sanford C. Bernstein lifted their price target on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. Citigroup lifted their price objective on Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. Finally, HSBC lifted their price objective on Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $192.94.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.